MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway

Published:2023-11 Issue: Volume:256 Page:109770
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Zhou Cheng,Sun Bao-Ye,Zhou Pei-yun,Yang Zhang-Fu,Wang Zhu-Tao,Liu Gao,Gan Wei,Wang Zheng,Zhou Jian,Fan Jia,Yi Yong,Ren Ning,Qiu Shuang-Jian

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Cancer incidence and mortality in China, 2015;Zhang;Journal of the National Cancer Center.,2021

2. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J. Hepatol.,2022

3. Effects of Sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma;Kuczynski;Cancer Res.,2015

4. Phase Ib study of Lenvatinib plus Pembrolizumab in patients with Unresectable hepatocellular carcinoma;Finn;J. Clin. Oncol.,2020

5. Atezolizumab plus bevacizumab versus Sorafenib in the Chinese subpopulation with Unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study;Qin;Liver cancer.,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sialylation-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in uterine corpus endometrial carcinoma;Cancer Cell International;2024-09-11

2. Targeting TNFR2 for cancer immunotherapy: recent advances and future directions;Journal of Translational Medicine;2024-09-02

3. Research on single-cell transcriptomics in hepatocellular carcinoma;Asia-Pacific Journal of Oncology;2024-08-07

4. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma;Drug Discovery Today;2024-08

5. Advances in hepatocellular carcinoma drug resistance models;Frontiers in Medicine;2024-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3